10-Q: SINTX Technologies Reports Q3 2024 Results, Announces Strategic Shift Towards Medical Devices

SINTX Technologies reported its Q3 2024 financial results, including a net loss, and announced a strategic shift towards the medical device sector, while ceasing operations at its armor plant.

Summary

• SINTX Technologies reported a net loss of $6.2 million for the three months ended September 30, 2024, and a net loss of $9.3 million for the nine months ended September 30, 2024.
• Product revenue increased by 118% to $367,000 for the quarter and 64% to $1.054 million for the nine months compared to the same periods in 2023.
• Grant and contract revenue decreased by 15% to $432,000 for the quarter but increased by 19% to $1.291 million for the nine months compared to the same periods in 2023.
• The company incurred a $4.5 million impairment charge related to the shutdown of its armor plant.
• A reduction in force resulted in expenses of approximately $407,000 during the quarter.
• The company is shifting its strategic focus towards the medical device sector, prioritizing the development and commercialization of innovative medical devices.
• SINTX is exploring strategic transactions, including acquisitions, partnerships, and a potential reverse merger.
• The company is also in discussions to reduce its lease liability at its Salt Lake City location.
• SINTX had 1,342,853 shares of common stock outstanding as of November 6, 2024.
• The company's cash and cash equivalents were $4.8 million as of September 30, 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with significant challenges. While there is positive revenue growth and a strategic shift towards a potentially lucrative sector, the substantial net losses, impairment charges, and going concern uncertainties weigh heavily on the overall sentiment. The company's reliance on additional funding and the risks associated with its strategic shift contribute to a negative outlook.

Positives

• Product revenue saw a substantial increase of 118% in the third quarter and 64% for the nine months ended September 30, 2024, indicating growing demand for the company's products.
• The strategic shift towards the medical device sector could lead to higher growth and profitability in the future.
• The company is actively seeking strategic transactions to strengthen its position in the medical device field.
• Discussions to reduce lease liabilities could lead to lower operating expenses.
• The company has secured additional funding through public offerings and its ATM agreement.

Negatives

• The company reported a net loss of $6.2 million for the quarter and $9.3 million for the nine months ended September 30, 2024.
• The impairment charge of $4.5 million related to the armor plant significantly impacted the company's financial results.
• The reduction in force, while aimed at cost savings, may impact the company's ability to execute its strategic objectives.
• The company's ability to continue as a going concern is dependent on its ability to increase sales, decrease expenses, and raise additional funding.
• The company has an accumulated deficit of $280 million as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is uncertain and dependent on securing additional funding.
• The strategic shift to the medical device sector may not be successful.
• The company may not be able to acquire revenue-generating assets.
• Delays in divesting the armor, aerospace, and defense segments could hinder the development of the medical device focus.
• The reduction in force may result in the company not having the necessary personnel to pursue its strategic objectives.
• The company's public float is below $75 million, limiting its ability to sell securities under its ATM agreement.
• The company remains subject to a Mandatory Panel Monitor by Nasdaq for one year from June 11, 2024, and could be delisted if it fails to maintain a minimum $1.00 closing bid price.

Future Outlook

The company is focusing on a strategic shift towards the medical device sector and is exploring various strategic transactions to support this transition. The company's future is dependent on its ability to increase sales, decrease expenses, and raise additional funding.

Management Comments

• The Board of Directors, together with management, is performing an ongoing evaluation of the Company's business strategy and focus.
• Eric Olson was appointed to the office of Chief Executive Officer and President to lead the evaluation process.
• The Board of Directors also entered into an engagement agreement with Ascendiant Partners to evaluate strategic transactions.
• An option being evaluated is a change in strategic emphasis to advancements in the medical device sector.
• Management will work with the insurance company to continue to fund the repair of the furnace.

Industry Context

The strategic shift towards medical devices aligns with a broader trend of companies focusing on high-growth sectors with strong demand. The company's expertise in advanced ceramics and biomaterials positions it well to compete in the medical device market, which is characterized by innovation and high regulatory hurdles. The company's focus on antimicrobial properties, enhanced imaging capabilities, and durability in its medical devices is also in line with current industry trends.

Comparison to Industry Standards

• SINTX's shift towards medical devices is similar to other materials science companies that have diversified into higher-margin healthcare applications, such as Medtronic and Stryker, which use advanced materials in their implants and surgical tools.
• The company's focus on silicon nitride is unique, as most medical implants use titanium, cobalt-chrome, or polymers. Companies like CeramTec and Kyocera also produce advanced ceramics, but SINTX's focus on silicon nitride for medical applications is a differentiator.
• The impairment charge related to the armor plant is a significant setback, and other companies in the defense sector, such as Lockheed Martin and Raytheon, have faced similar challenges with specific projects, but they have the scale and diversification to absorb such losses.
• SINTX's revenue growth in the third quarter is positive, but it is still operating at a loss, which is not uncommon for early-stage medical device companies. Companies like Inari Medical and Shockwave Medical have also experienced losses in their early stages while investing in R&D and commercialization.
• The company's reliance on public offerings and ATM agreements for funding is typical for smaller companies in the medical device sector, but it also highlights the need for a sustainable revenue model. Companies like Nevro and Axonics have also used similar funding strategies in their early stages.

Management Changes

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and going concern uncertainties.
• Employees have been impacted by the reduction in force.
• Customers may experience changes in product offerings as the company shifts its strategic focus.
• Suppliers may be affected by the company's financial challenges and strategic changes.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company will continue to evaluate strategic transactions, including acquisitions, partnerships, and a potential reverse merger.
• The company will continue discussions with the leaseholder to reduce its lease liability.
• The company will work with the insurance company to continue to fund the repair of the sintering furnace.
• The company will focus on the development and commercialization of innovative medical devices.

Key Dates

Keywords

medical devices, silicon nitride, advanced ceramics, strategic shift, armor plant, financial results, public offering, ATM agreement, impairment charge, reduction in force